This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://linked.opendata.cz/resource/drugbank/drug/DB00267/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/mesh/concept/
n19http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00267/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00267/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00267/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00267/identifier/kegg-drug/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00267
rdf:type
n3:Drug
n3:description
Cefmenoxime is a third-generation cephalosporin antibiotic. [Wikipedia]
n3:generalReferences
# Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T: [Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis] Jpn J Antibiot. 1995 May;48(5):602-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7637194 # Paladino JA, Fell RE: Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994 Mar;28(3):384-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8193431 # Duncker GI, Reich U, Krausse R: Cefmenoxime in corneal organ culture. Ophthalmologica. 1994;208(5):262-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7816419 # Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y: Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6941742
n3:group
approved
n3:halfLife
1 hour
n3:indication
Used to treat female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria.
n3:manufacturer
n12:271B43A3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00267 n19:DB00267
dcterms:title
Cefmenoxime
adms:identifier
n8:Cefmenoxime n9:PA164750569 n15:D01739 n16:55490 n17:DB00267
n3:mechanismOfAction
The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefmenoxime is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.
n3:synonym
(6R,7R)-7-[[(2e)-2-(2-amino-1,3-Thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (iupac) Cefmenoxima (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure Cefmenoximum
n3:toxicity
Information on cefmenoxime overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
n3:proteinBinding
50-70%
n3:salt
n3:synthesisReference
Yasushi Morita, "Method for preventing coloration of aqueous preparations of cefmenoxime." U.S. Patent US4808577, issued November, 1985.
n10:hasConcept
n11:M0023523
n3:IUPAC-Name
n4:271B43A8-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B43AE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B43AD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B43AA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B43AB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B43AC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B43A6-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B43A7-363D-11E5-9242-09173F13E4C5 n4:271B43BE-363D-11E5-9242-09173F13E4C5 n4:271B43A4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B43A5-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:J01DD05
n3:H-Bond-Acceptor-Count
n4:271B43B4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B43B5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B43AF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B43B0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B43B2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B43B1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B43B3-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is approximately 100% following intramuscular injection.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
65085-01-0
n3:category
n3:Bioavailability
n4:271B43BA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B43BC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B43BD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B43B9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B43B8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B43BB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B43A9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B43B6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B43B7-363D-11E5-9242-09173F13E4C5